oxaliplatin + tegafur-uracil

Oxaliplatin + tegafur-uracil is a combination chemotherapy regimen used primarily in the treatment of gastrointestinal cancers, such as colorectal and gastric cancer. Oxaliplatin is a third-generation platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA replication and transcription, leading to cell death. Tegafur is an oral prodrug of 5-fluorouracil (5-FU), which after hepatic conversion releases 5-FU to inhibit thymidylate synthase and disrupt DNA synthesis. Uracil acts as a competitive inhibitor of dihydropyrimidine dehydrogenase (DPD), thereby increasing the bioavailability and efficacy of 5-FU by preventing its rapid degradation. The combination leverages the cytotoxic effects of both agents for enhanced antitumor activity[1][4]. This regimen may be used in various protocols for advanced or metastatic colorectal cancer and has also been studied in gastric cancer settings[3].

Other names

oxaliplatin plus tegafur/uraciloxaliplatin + UFT